-
Je něco špatně v tomto záznamu ?
Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000-2021: a population-based cohort study
G. Corby, NL. Barclay, EH. Tan, E. Burn, A. Delmestri, T. Duarte-Salles, A. Golozar, WY. Man, I. Tietzova, D. Prieto-Alhambra, D. Newby
Status neindexováno Jazyk angličtina Země Čína
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2012
PubMed Central
od 2012
Europe PubMed Central
od 2012
PubMed
39430337
DOI
10.21037/tlcr-24-241
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Lung cancer is the leading cause of cancer-associated mortality worldwide. In the United Kingdom (UK), there has been a major reduction in smoking, the leading risk factor for lung cancer. Therefore, an up-to-date assessment of the trends of lung cancer is required in the UK. This study aims to describe lung cancer burden and trends in terms of incidence, prevalence, and survival from 2000-2021, using two UK primary care databases. METHODS: We performed a population-based cohort study using the UK primary care Clinical Practice Research Datalink (CPRD) GOLD database, compared with CPRD Aurum. Participants aged 18+ years, with 1-year of prior data availability, were included. We estimated lung cancer incidence rates (IRs), period prevalence (PP), and survival at 1, 5 and 10 years after diagnosis using the Kaplan-Meier (KM) method. RESULTS: Overall, 11,388,117 participants, with 45,563 lung cancer cases were studied. The IR of lung cancer was 52.0 [95% confidence interval (CI): 51.5 to 52.5] per 100,000 person-years, with incidence increasing from 2000 to 2021. Females aged over 50 years of age showed increases in incidence over the study period, ranging from increases of 8 to 123 per 100,000 person-years, with the greatest increase in females aged 80-89 years. Alternatively, for males, only cohorts aged over 80 years showed increases in incidence over the study period. The highest IR was observed in people aged 80-89 years. PP in 2021 was 0.18%, with the largest rise seen in participants aged over 60 years. Median survival post-diagnosis increased from 6.6 months in those diagnosed between 2000-2004 to 10.0 months between 2015-2019. Both short and long-term survival was higher in younger cohorts, with 82.7% 1-year survival in those aged 18-29 years, versus 24.2% in the age 90+ years cohort. Throughout the study period, survival was longer in females, with a larger increase in survival over time than in males. CONCLUSIONS: The incidence and prevalence of lung cancer diagnoses in the UK have increased, especially in female and older populations, with a small increase in median survival. This study will enable future comparisons of overall disease burden, so the overall impact may be seen.
Department of Medical Informatics Erasmus University Medical Center Rotterdam The Netherlands
Odysseus Data Services Cambridge MA USA
OHDSI Center at the Roux Institute Northeastern University Boston MA USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002447
- 003
- CZ-PrNML
- 005
- 20250123101931.0
- 007
- ta
- 008
- 250117s2024 cc f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21037/tlcr-24-241 $2 doi
- 035 __
- $a (PubMed)39430337
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a cc
- 100 1_
- $a Corby, George $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK
- 245 10
- $a Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000-2021: a population-based cohort study / $c G. Corby, NL. Barclay, EH. Tan, E. Burn, A. Delmestri, T. Duarte-Salles, A. Golozar, WY. Man, I. Tietzova, D. Prieto-Alhambra, D. Newby
- 520 9_
- $a BACKGROUND: Lung cancer is the leading cause of cancer-associated mortality worldwide. In the United Kingdom (UK), there has been a major reduction in smoking, the leading risk factor for lung cancer. Therefore, an up-to-date assessment of the trends of lung cancer is required in the UK. This study aims to describe lung cancer burden and trends in terms of incidence, prevalence, and survival from 2000-2021, using two UK primary care databases. METHODS: We performed a population-based cohort study using the UK primary care Clinical Practice Research Datalink (CPRD) GOLD database, compared with CPRD Aurum. Participants aged 18+ years, with 1-year of prior data availability, were included. We estimated lung cancer incidence rates (IRs), period prevalence (PP), and survival at 1, 5 and 10 years after diagnosis using the Kaplan-Meier (KM) method. RESULTS: Overall, 11,388,117 participants, with 45,563 lung cancer cases were studied. The IR of lung cancer was 52.0 [95% confidence interval (CI): 51.5 to 52.5] per 100,000 person-years, with incidence increasing from 2000 to 2021. Females aged over 50 years of age showed increases in incidence over the study period, ranging from increases of 8 to 123 per 100,000 person-years, with the greatest increase in females aged 80-89 years. Alternatively, for males, only cohorts aged over 80 years showed increases in incidence over the study period. The highest IR was observed in people aged 80-89 years. PP in 2021 was 0.18%, with the largest rise seen in participants aged over 60 years. Median survival post-diagnosis increased from 6.6 months in those diagnosed between 2000-2004 to 10.0 months between 2015-2019. Both short and long-term survival was higher in younger cohorts, with 82.7% 1-year survival in those aged 18-29 years, versus 24.2% in the age 90+ years cohort. Throughout the study period, survival was longer in females, with a larger increase in survival over time than in males. CONCLUSIONS: The incidence and prevalence of lung cancer diagnoses in the UK have increased, especially in female and older populations, with a small increase in median survival. This study will enable future comparisons of overall disease burden, so the overall impact may be seen.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Barclay, Nicola L $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK
- 700 1_
- $a Tan, Eng Hooi $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK
- 700 1_
- $a Burn, Edward $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK
- 700 1_
- $a Delmestri, Antonella $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK
- 700 1_
- $a Duarte-Salles, Talita $u Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain $u Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
- 700 1_
- $a Golozar, Asieh $u Odysseus Data Services, Cambridge, MA, USA $u OHDSI Center at the Roux Institute, Northeastern University, Boston, MA, USA
- 700 1_
- $a Man, Wai Yi $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK
- 700 1_
- $a Tietzova, Ilona $u First Department of Tuberculosis and Respiratory Diseases, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Prieto-Alhambra, Daniel $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK $u Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands $1 https://orcid.org/0000000239506346
- 700 1_
- $a Newby, Danielle $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK
- 773 0_
- $w MED00186389 $t Translational lung cancer research $x 2218-6751 $g Roč. 13, č. 9 (2024), s. 2187-2201
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39430337 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250117 $b ABA008
- 991 __
- $a 20250123101925 $b ABA008
- 999 __
- $a ok $b bmc $g 2254579 $s 1238450
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 13 $c 9 $d 2187-2201 $e 20240921 $i 2218-6751 $m Translational lung cancer research $n Transl Lung Cancer Res $x MED00186389
- LZP __
- $a Pubmed-20250117